Trimethoprim
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
| |
| Trimethoprim
| |
| Systematic (IUPAC) name | |
| 5-(3,4,5-trimethoxybenzyl)pyrimidine-2,4-diamine | |
| Identifiers | |
| CAS number | |
| ATC code | J01 |
| PubChem | |
| DrugBank | |
| Chemical data | |
| Formula | C14H18N4O3 |
| Mol. mass | 290.32 g/mol |
| Pharmacokinetic data | |
| Bioavailability | 90–100% |
| Metabolism | hepatic |
| Half life | 8–10 hours |
| Excretion | renal 50–60% |
| Therapeutic considerations | |
| Pregnancy cat. | |
| Legal status | |
| Routes | Oral |
|
WikiDoc Resources for Trimethoprim | |
|
Articles | |
|---|---|
|
Most recent articles on Trimethoprim Most cited articles on Trimethoprim | |
|
Media | |
|
Powerpoint slides on Trimethoprim | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Trimethoprim at Clinical Trials.gov Clinical Trials on Trimethoprim at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Trimethoprim
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Trimethoprim Discussion groups on Trimethoprim Patient Handouts on Trimethoprim Directions to Hospitals Treating Trimethoprim Risk calculators and risk factors for Trimethoprim
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Trimethoprim | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Trimethoprim (INN) (IPA: [traɪˈmɛθəprɪm]) is a bacteriostatic antibiotic mainly used in the prophylaxis and treatment of urinary tract infections. It belongs to the class of chemotherapeutic agents known as dihydrofolate reductase inhibitors. Trimethoprim was formerly marketed by GlaxoWellcome under trade names including Proloprim, Monotrim and Triprim; but these trade names have been licensed to various generic pharmaceutical manufacturers. In clinical use it is often abbreviated TRI or TMP; its common laboratory abbreviation is W.
Mechanism of action
Trimethoprim acts by interfering with the action of bacterial dihydrofolate reductase, inhibiting synthesis of tetrahydrofolic acid. Tetrahydrofolic acid is an essential precursor in the de novo synthesis of the DNA nucleotide thymine. Bacteria are unable to take up folic acid from the environment (i.e. the infection host) and are thus dependent on their own de novo synthesis. Inhibition of the enzyme starves the bacteria of bases necessary for DNA replication.
Co-trimoxazole
Trimethoprim was commonly used in combination with sulfamethoxazole, a sulfonamide antibiotic, which inhibits an earlier step in the folate synthesis pathway (see diagram above). This combination, also known as co-trimoxazole, TMP-sulfa, or TMP-SMX, results in an in vitro synergistic antibacterial effect by inhibiting successive steps in folate synthesis, this claimed benefit was not seen in general clinical use.[1] [1] Its use has been declining due to reports of sulfamethoxazole bone marrow toxicity, resistance and lack greater efficacy in treating common urine and chest infections,[1][1][1][1] and side effects of antibacterial sulfonamides. As a consequence, the use of co-trimoxazole was restricted in 1995.[1]
Clinical indications
Trimethoprim, used as monotherapy, is indicated for the prophylaxis and treatment of urinary tract infections (cystitis). Co-trimoxazole, with its greater efficacy against a limited number of bacteria, remains indicated for some infections; for example, it is used as prophylaxis in patients at risk for Pneumocystis jirovecii pneumonia (e.g. AIDS patients and those with some hematological malignancies) and as therapy in Whipple's disease.
Footnotes
External links
- Nucleic acid inhibitors (PDF file).
Acne-treating agents (D10) | |
|---|---|
| Topical agents | Azelaic acid • Benzoyl peroxide • Glycolic acid • Light therapy • Salicylic acid • Tea tree oil |
| Antibiotics | Clindamycin • Erythromycin • Sulfacetamide • Tetracyclines • Trimethoprim |
| Hormonal | Antiandrogens • Contraceptives |
| Retinoids | Adapalene • Isotretinoin • Tazarotene • Tretinoin |
Antibacterials for systemic use: sulfonamides (sulfa drugs) and trimethoprim (J01E) | |
|---|---|
| Trimethoprim and derivatives | Trimethoprim • Brodimoprim |
| Short-acting sulfonamides | Sulfaisodimidine • Sulfamethizole • Sulfadimidine • Sulfapyridine • Sulfafurazole • Sulfanilamide • Sulfathiazole • Sulfathiourea |
| Intermediate-acting sulfonamides | Sulfamethoxazole • Sulfadiazine • Sulfamoxole |
| Long-acting sulfonamides | Sulfadimethoxine • Sulfalene • Sulfametomidine • Sulfametoxydiazine • Sulfamethoxypyridazine • Sulfaperin • Sulfamerazine • Sulfaphenazole • Sulfamazon |
| Combinations | Sulfamethoxazole and trimethoprim |
| Other | Mafenide • Prontosil • Sulfacetamide • Sulfasalazine • Sulfisoxazole |
de:Trimethoprim hu:Trimetoprimsk:Trimetoprim sv:Trimetoprim th:ไตรเมโทพริม
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
